Chemotherapy resistance mechanisms in advanced skin cancer

Bhuvanesh Sukhlal Kalal, Dinesh Upadhya, Vinitha Ramanath Pai

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5%. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma.

Original languageEnglish
Pages (from-to)19-25
Number of pages7
JournalOncology Reviews
Volume11
Issue number1
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Skin Neoplasms
Melanoma
Drug Therapy
Radiotherapy
Therapeutics
Combination Drug Therapy
Drug Resistance
Early Diagnosis
Public Health
Apoptosis
Incidence
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kalal, Bhuvanesh Sukhlal ; Upadhya, Dinesh ; Pai, Vinitha Ramanath. / Chemotherapy resistance mechanisms in advanced skin cancer. In: Oncology Reviews. 2017 ; Vol. 11, No. 1. pp. 19-25.
@article{b682541d6fa04c02b25218e402449872,
title = "Chemotherapy resistance mechanisms in advanced skin cancer",
abstract = "Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5{\%}. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma.",
author = "Kalal, {Bhuvanesh Sukhlal} and Dinesh Upadhya and Pai, {Vinitha Ramanath}",
year = "2017",
month = "1",
day = "1",
doi = "10.4081/oncol.2017.326",
language = "English",
volume = "11",
pages = "19--25",
journal = "Oncology Reviews",
issn = "1970-5557",
publisher = "PagePress",
number = "1",

}

Chemotherapy resistance mechanisms in advanced skin cancer. / Kalal, Bhuvanesh Sukhlal; Upadhya, Dinesh; Pai, Vinitha Ramanath.

In: Oncology Reviews, Vol. 11, No. 1, 01.01.2017, p. 19-25.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Chemotherapy resistance mechanisms in advanced skin cancer

AU - Kalal, Bhuvanesh Sukhlal

AU - Upadhya, Dinesh

AU - Pai, Vinitha Ramanath

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5%. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma.

AB - Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5%. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85018680156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018680156&partnerID=8YFLogxK

U2 - 10.4081/oncol.2017.326

DO - 10.4081/oncol.2017.326

M3 - Review article

VL - 11

SP - 19

EP - 25

JO - Oncology Reviews

JF - Oncology Reviews

SN - 1970-5557

IS - 1

ER -